CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Hydroxychloroquine Sulfate 600 mg once a dayWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (4)

Name (Synonyms) Correlation
drug1110 Hydroxychloroquine Sulfate 400 mg twice a day Wiki 1.00
drug628 Conestat alfa Wiki 1.00
drug1112 Hydroxychloroquine Sulfate 600 mg twice a day Wiki 1.00
drug1853 Placebo oral tablet Wiki 0.19

Correlated MeSH Terms (4)

Name (Synonyms) Correlation
D003141 Communicable Diseases NIH 0.09
D007239 Infection NIH 0.06
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine)

The PATCH trial (Prevention And Treatment of COVID-19 with Hydroxychloroquine) is funded investigator-initiated trial that includes 3 cohorts. Cohort 1: a double-blind placebo controlled trial of high dose HCQ as a treatment for home bound COVID-19 positive patients; Cohort 2: a randomized study testing different doses of HCQ in hospitalized patients; Cohort 3: a double blind placebo controlled trial of low dose HCQ as a preventative medicine in health care workers.

NCT04329923 COVID-19 Drug: Hydroxychloroquine Sulfate 400 mg twice a day Drug: Hydroxychloroquine Sulfate 600 mg twice a day Drug: Hydroxychloroquine Sulfate 600 mg once a day Drug: Placebo oral tablet

Primary Outcomes

Description: Cohort 1 (home quarantined COVID-19 patients): Median time to release from quarantine by meeting the following criteria: 1) No fever for 72 hours 2) improvement in other symptoms and 3) 7 days have elapsed since the beginning of symptom onset.

Measure: Median release from quarantine time

Time: 14 days or less

Description: Cohort 2 (hospitalized COVID-19 patients): Rate of participants discharged at or before 14 days

Measure: Rate of hospital discharge

Time: 14 days

Description: Cohort 3 Physicians and nurse prophylaxis: Rate of COVID-19 infection at 2 months

Measure: Rate of infection

Time: 2 months

Secondary Outcomes

Description: Cohort 1 rate of participant-reported secondary infection of housemates

Measure: Rate of housemate infection

Time: 14 days

Description: Cohort 1 rate of hospitalization

Measure: Rate of hospitalization

Time: 14 days

Description: Cohort 1 rate of treatment related adverse events

Measure: Cohort 1 adverse event rate

Time: 14 days

Description: Cohort 2 Time to condition appropriate for discharge. The primary care team indicates the patients has improved to the point of being discharged.

Measure: Time to condition appropriate for discharge

Time: 14 days

Description: Cohort 2 rate of ICU admission from a floor bed in the hospital

Measure: Rate of ICU admission

Time: 14 days

Description: Cohort 2 the number of days between hospital admission and a negative PCR test for SARS-CoV-2.

Measure: Time to PCR negativity

Time: 14 days

Description: Cohort 2 rate of treatment related adverse events

Measure: Cohort 2 adverse events

Time: 14 days

Description: Cohort 3 number of scheduled shifts at the hospital that are missed.

Measure: Scheduled shifts missed

Time: 2 months

Description: Cohort 3 rate of treatment related adverse events

Measure: Cohort 3 adverse events

Time: 2 months

No related HPO nodes (Using clinical trials)